Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
No public readout found for HEM1036 Phase 2 (NCT05527301). Trial status not recruiting or unknown per sources; primary completion estimated Jan 2026. No topline results, efficacy data, or sponsor announcements identified in web searches as of Apr 2026.
Found Apr 6, 2026, 2:57 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial status listed as Unknown on ClinicalTrials.gov with estimated primary completion Jan 2026. No public results, topline readout, or efficacy statements found in web searches. No sources frame this specific Phase 2 trial as positive or negative.
Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:23 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as unknown with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:52 PMReviewed Apr 4, 2026, 10:33 PM
NO_DECISIONDismissed84% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No clear trial-specific public efficacy readout was found. The registry identifies the Phase 2 LARS study and endpoint, while the sponsor’s current pipeline still describes H1036 for LARS only as Phase 2a approved, without outcome language. That is insufficient to call the readout positive or negative.
Found Apr 3, 2026, 5:20 PMReviewed Apr 3, 2026, 5:20 PM
NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No clear public readout for this exact Phase 2 trial was found. The trial record still shows no trial-specific outcome data, and recent HEM Pharma materials discuss the LARS program as HEMP-002 at Australia Phase 2a/HREC-IND stage rather than reporting completed HEM1036 Phase 2 efficacy results.
Found Apr 2, 2026, 5:14 PMReviewed Apr 3, 2026, 4:48 PM
NO_DECISIONDismissed90% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No clear public Phase 2 readout was found. The trial registry still points to an estimated primary completion of 2026-01-01, and the sponsor’s current pipeline still describes HEM1036/HEMP-002 only as Australia HREC clinical 2a approved, not as having reported efficacy results. Publicly found coverage was about trial approval/start, not outcomes.
Found Mar 31, 2026, 9:42 PMReviewed Apr 1, 2026, 6:34 AM
NO_DECISIONDismissed82% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
I found no clear public, trial-specific Phase 2 efficacy readout for NCT05527301. The registry listing identifies this as a Phase 2 placebo-controlled study with primary completion dated 2026-01-01, but I did not find posted results or a sponsor press release interpreting this exact trial as positive or negative. The sponsor materials I found describe HEM1036 as still being clinically advanced and refer only to earlier preliminary efficacy observations in LARS patients, not the randomized Phase 2 readout for NCT05527301. Because the available evidence is incomplete and not a clear trial-specific public outcome, the correct label is no_decision.
Found Mar 30, 2026, 4:33 AMReviewed Apr 1, 2026, 6:35 AM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT05527301 | HEM1036 Phase 2 Study in Low Anterior Resection Syndrome | ClinicalTrials.gov
ClinicalTrials.gov lists NCT05527301 as a double-blind, randomized, placebo-controlled Phase 2 study of HEM1036 in Low Anterior Resection Syndrome. The search result snippet states the study is designed to explore efficacy and safety in subjects with LARS.
Web Searchbiotechhunter.com
NCT05527301 - HEM1036 Phase 2 Study in Low Anterior Resection Syndrome | Biotech Hunter
This trial tracker page for NCT05527301 describes the study as Phase 2, not yet recruiting, with start date January 1, 2024, primary completion date January 1, 2026, and study completion date January 1, 2026.
Sponsorfinancialreports.eu
HEM Pharma Inc. - Annual Report 2023
The sponsor's annual report says HEM1036 is a single live biotherapeutic product, that safety was confirmed through in vitro, in vivo, and toxicity testing, that symptom improvement was seen in a preliminary efficacy clinical study in LARS patients, and that the company received HREC approval in Australia to conduct a LARS drug clinical trial. It also says the company is planning additional preliminary efficacy work to expand the indication.